The Peer’s lab work at the interface of materials science, chemistry, molecular biology, and immunology, to discover and validate novel therapeutic targets at the molecular level, and to develop specific molecular medicines for therapeutics and disease management.
The lab is highly dynamic, multidisciplinary, and focuses on developing targeted vehicles for cell-specific delivery of novel molecular medicines using RNAi , mRNA, saRNA, DNA and novel genome editing strategies. The lab goal is to translate academic discoveries into innovative therapeutic modalities. With that in mind, Prof. Peer also founded SPARK Tel Aviv to accelerate cures via academic discoveries. Prof. Peer strives to develop the career of young students and encourage them to fulfill their ambitions and dreams.
We aspire to utilize oligonucleotides loaded LNPs for in vivo reprograming of leukocytes and thus to design novel immunomodulatory therapeutic approaches for autoimmune disorders and cancer.
The goal of this project is to explore resistance pathways of cancer cells and translate the acquired knowledge by designing novel RNAi-based nanotherapeutics.
We aim to utilize RNA-loaded lipid nanoparticles in order to design new therapeutic modalities for various malignancies, including head & neck cancer, glioblastoma and breast cancer.
We aim to design novel platforms for a selective delivery of therapeutic payload to specific target cells, thus increasing the efficiency and reducing adverse effects.
This research aims to broaden the nanotechnology toolbox by designing new, highly efficient, methodologies for nucleic acids delivery.
The Peer lab is designing novel methodologies to manipulate cells’ function in vivo, using targeted, safe, lipid nanoparticles. They are utilizing nanotechnology tools to generate novel therapeutic strategies for inflammatory diseases and cancers. The lab is combining multidisciplinary approaches including immunology, cell and molecular biology, genetics, protein engineering, material sciences, nanotechnology and computational techniques for drug discovery. In addition, they are designing highly selective targeted nanocarriers able to reprogram cells in a discerning manner, with an ultimate goal to translate the findings into clinical settings.
Srinivas Ramishetti*, Ranit Kedmi*, Meir Goldsmith, Fransisca Leonard, Andrew G. Sprague, Biana Godin, Michael Gozin, Pieter R. Cullis, Derek M. Dykxhoorn, and Dan Peer
Nuphar Veiga, Meir Goldsmith, Yasmin Granot, Daniel Rosenblum, Niels Dammes, Ranit Kedmi, Srinivas Ramishetti & Dan Peer